BG45
BG45 is a potent HDAC3 inhibitor with IC50 values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis[1][2].
Product Specifications
CAS Number
[926259-99-6]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Caspase; HDAC
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BG45.html
Purity
99.95
Solubility
DMSO : ≥ 48 mg/mL
Smiles
O=C(C1=NC=CN=C1)NC2=CC=CC=C2N
Molecular Formula
C11H10N4O
Molecular Weight
214.22
Precautions
H302, H315, H319, H335
References & Citations
[1]Minami J, et, al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014 Mar;28 (3) :680-9.|[2]Iaconelli J, et, al. HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells. ACS Chem Biol. 2015 Mar 20;10 (3) :883-90.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC2; HDAC3; HDAC6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
